SCGE

Vesigen Receives National Institutes of Health Award in Targeted Genome Editor Delivery Challenge

Retrieved on: 
Tuesday, December 19, 2023
Biotechnology, Genetics, Health, SCGE, RNA, Gene editing, Cell, Therapy, Tropism, Genome, Bangladesh Technical Education Board, NIH, Vaccine

Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED (Targeted Genome Editor Delivery) Challenge .

Key Points: 
  • Vesigen Therapeutics, Inc., a biotechnology company developing a novel non-viral delivery platform for gene editors, RNA, and protein-based therapeutics, was selected as a Phase 1 winner of the National Institutes of Health TARGETED (Targeted Genome Editor Delivery) Challenge .
  • The Company’s proposal, “Engineered ARMMs: Promising Human-Derived Vectors for Cell Type-Specific Delivery of Genome Editors”, builds on recent data demonstrating directed tropism of the Company’s non-viral ARMM (ARrestin-domain 1 Mediated Microvesicles) delivery platform and was among five proposals selected as “Winning Solutions” for programmable delivery systems for gene editing.
  • We look forward to advancing our platform toward the clinic and unlocking the full potential of genetic medicines.”
    The NIH launched the TARGETED Challenge to advance genome editing technology by sourcing innovative solutions for delivering genome editing components safely and effectively.
  • The three-phase challenge supports the NIH's Somatic Cell Genome Editing (SCGE) commitment to developing targeted delivery systems for delivering genome editors to somatic cells in the body.

Couragene Co-founders Developing Gene Editing Technology for Genetic Diseases Awarded Major Federal Grant

Retrieved on: 
Tuesday, October 10, 2023
Research, FDA, Genetics, Stem Cells, Biotechnology, Health, Pharmaceutical, Science, Oncology, SCGE, Acquisition, Angelman syndrome, Genome, Central nervous system, Trace (linear algebra), STEP, Patient, Gene editing, UBE3A, DSM-IV codes, Yale University, Rush University, NIH, Pharmaceutical industry, Vaccine

This monumental grant, totaling roughly $40 million contingent on milestones, marks a momentous step forward in leveraging genome editing to combat neurogenetic diseases.

Key Points: 
  • This monumental grant, totaling roughly $40 million contingent on milestones, marks a momentous step forward in leveraging genome editing to combat neurogenetic diseases.
  • Leveraging the STEP technology, a team led by Professors Jiang and Zhou devised a precise genome editing approach directly addressing the disease-causing genetic defects.
  • Couragene exclusively licensed these innovative technologies and is poised to make a profound and lasting impact on the future treatment of genetic disorders.
  • Couragene is a biotechnology company committed to building first-in-class in vivo genetic therapies using its proprietary delivery platforms.

Research to develop new rare disease therapies underway at The Jackson Laboratory

Retrieved on: 
Tuesday, June 6, 2023
Tissue, Huntington's disease, DNA, CRISPR, Broad Institute, Therapy, Spinal muscular atrophy, DSM-IV codes, Boston Children's Hospital, Rett syndrome, Hope, Research, Jackson Laboratory, Associate, Friedreich's ataxia, National Institute of Neurological Disorders and Stroke, SCGE, University of Texas Southwestern Medical Center, Patient, Risk, Nervous system, JAX, NINDS, Hospital, Rare, FDA, Massachusetts General Hospital, BAR, Lutz, IND, Disease, Vaccine, Pharmaceutical industry, Stroke

 BAR HARBOR, Maine, June 6, 2023 /PRNewswire/ -- Researchers led by Cathleen Lutz, Ph.D., are using an exciting new method, preclinical genomic editing, to develop safe, effective therapies for rare diseases and bring them to the clinic.

Key Points: 
  • Unfortunately, the translation of the accumulated knowledge to safe and effective therapies has lagged.
  • Researchers are therefore still hard at work to develop safer therapies for rare genetic diseases that provide lasting benefit.
  • Now Cathleen Lutz , Ph.D., of The Jackson Laboratory (JAX) is spearheading a major effort to implement a new genomic research tool—preclinical genomic editing—to cure rare neurological genetic diseases.
  • Collectively they seek to close the gap between preclinical research that has produced promising rare disease therapy strategies and the actual clinical delivery of safe and effective treatments to patients.

Global Gene Editing Technology Markets and Investment Opportunities Report 2023: Analysis by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - ResearchAndMarkets.com

Retrieved on: 
Wednesday, February 15, 2023
Biotechnology, Genetics, Health, Analysis, Gene editing, SCGE, Hope, Rare, Competitive landscape, Bangladesh Technical Education Board, NIH, Verve, Acquisition, Patient, CRISPR, Research, Climate change, Food, Local Investing Opportunity Network, Food security, Disease, Growth, Regeneron Pharmaceuticals, Cancer, Collection, Pharmaceutical industry, Vaccine, Agriculture, Pfizer, Bayer

The "Global Gene Editing Technology Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Gene Editing Technology Business and Investment Opportunities - Analysis & Market Size by Technology, Clinical Trials, Patents, Financial Deals, Competitive Landscape - Q1 2023 Update" report has been added to ResearchAndMarkets.com's offering.
  • Gene editing technology has emerged as one of the fastest-growing areas in the global healthcare sector.
  • It provides a detailed analysis of gene editing market dynamics, covering clinical trials, patent data, financial deals, and company profiling details.
  • In addition, this report provides analyst commentary on key trends, drivers, strategies, innovations, and regulations in gene editing technology sector.

U.S. Gene Editing Market Report 2022: Diversified Application Areas of Gene Editing Fuels Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, November 22, 2022
Biotechnology, Pharmaceutical, Genetics, Health, Agriculture, Investment, Zinc finger nuclease, Gene editing, Biomedical Research, Cell, Genome, Transcription activator-like effector nuclease, Potency (pharmacology), Genetic engineering, Mutation, DNA, Veterinary medicine, Human, Research, SCGE, Tissue, NIH, Therapy, Growth, Medicine, Drug discovery, Genomics, Gene, DNA-directed RNA interference, Antibiotics, Vaccine, CRISPR

The U.S. gene editing market is expected to grow at a CAGR of 21.13% during 2022-2027.

Key Points: 
  • The U.S. gene editing market is expected to grow at a CAGR of 21.13% during 2022-2027.
  • Unlike genetic engineering, which randomly incorporates genetic material into the host genome, gene editing aims to make changes at specific target locations.
  • Genome editing technology is a technique for target gene modification that allows the knockout and addition of specific fragments of DNA.
  • These are some of the factors that are boosting the growth of the U.S. gene editing market.

EQS-News: Freelancer wins US$6.7m task order with NASA and the National Institutes of Health in gene editing

Retrieved on: 
Thursday, September 29, 2022
National, OSC, ASX, Central nervous system, Division of Program Coordination, Planning, and Strategic Initiatives, Time, Efficiency, Gene editing, FLN, Australian Securities Exchange, Copywriting, Achievement, OTCQX, Program, Internet, Technology, Cell, Tissue, Escrow.com, Office for Strategic Coordination of Health Research, Research, NASA, Marketing, SCGE, NIH, Cas9, Vaccine

50%+ editing efficiency) non-viral delivery system capable of crossing the blood brain barrier to deliver genome editing machinery to a majority of target cell types in the central nervous system.

Key Points: 
  • 50%+ editing efficiency) non-viral delivery system capable of crossing the blood brain barrier to deliver genome editing machinery to a majority of target cell types in the central nervous system.
  • 3+ configurations) delivery system to deliver genome editing machinery that can target specific tissues or cell types.
  • It is expected that FLN will generate approximately US$700,000 in net revenue contribution for this task order.
  • SCGE is developing quality tools to perform and assess effective and safe genome editing in non-reproductive (somatic) cells of the body.

Collibra Raises $250 Million in Funding Round Led by Sequoia Capital Global Equities and Sofina, More than Doubling its Valuation to $5.25 Billion

Retrieved on: 
Tuesday, November 9, 2021
Cloud, Intelligence, View, Language, Software as a service, Sequoia, Industry, Ecosystem, Privacy, Google Cloud, Global 2000, Government, Engineering, Organization, CEO, Tiger Global Management, Technology, Growth, Catalog, Investment, Multimedia, Software, BI, API, Common, Partnership, Twitter, UiPath, Internet, CapitalG, Snowflake, IPO, LinkedIn, Solution, Battery Ventures, SCGE, Data science, Tableau, Telecom data intelligence, Sequoia Capital, AWS, Ali Baba, Euronext, Procore, Cryptocurrency, Marketing

Sequoia Capital Global Equities (SCGE) and Sofina led the round, along with participation from new investor Tiger Global Management and existing investors Battery Ventures, CapitalG, Dawn Capital, Durable Capital Partners LP, ICONIQ Capital and Index Ventures.

Key Points: 
  • Sequoia Capital Global Equities (SCGE) and Sofina led the round, along with participation from new investor Tiger Global Management and existing investors Battery Ventures, CapitalG, Dawn Capital, Durable Capital Partners LP, ICONIQ Capital and Index Ventures.
  • The funding values Collibra at $5.25 billion, more than doubling the company's valuation of $2.35 billion announced in April 2020.
  • The Global 2000 relies on Collibra to create the critical alignment that accelerates workflows and delivers better results faster.
  • Sequoia Capital Global Equities (SCGE) is a public/private crossover fund, with investments spanning from late-stage private companies to public companies.

Collibra Raises $250 Million in Funding Round Led by Sequoia Capital Global Equities and Sofina, More than Doubling its Valuation to $5.25 Billion

Retrieved on: 
Tuesday, November 9, 2021
Cloud, Intelligence, Language, Software as a service, Sequoia, Industry, Ecosystem, Privacy, Google Cloud, Global 2000, Government, Engineering, Organization, CEO, Tiger Global Management, Technology, Growth, Catalog, Investment, Software, BI, API, Common, Partnership, Twitter, UiPath, Internet, CapitalG, Snowflake, IPO, LinkedIn, Solution, Battery Ventures, SCGE, Data science, Tableau, Telecom data intelligence, Sequoia Capital, AWS, Ali Baba, Euronext, Procore, Cryptocurrency, Marketing

NEW YORK and BRUSSELS, Nov. 9, 2021 /PRNewswire/ -- Collibra, the Data Intelligence company, today announced that it has raised $250 million in Series G funding. Sequoia Capital Global Equities (SCGE) and Sofina led the round, along with participation from new investor Tiger Global Management and existing investors Battery Ventures, CapitalG, Dawn Capital, Durable Capital Partners LP, ICONIQ Capital and Index Ventures. The funding values Collibra at $5.25 billion, more than doubling the company's valuation of $2.35 billion announced in April 2020.

Key Points: 
  • Sequoia Capital Global Equities (SCGE) and Sofina led the round, along with participation from new investor Tiger Global Management and existing investors Battery Ventures, CapitalG, Dawn Capital, Durable Capital Partners LP, ICONIQ Capital and Index Ventures.
  • The funding values Collibra at $5.25 billion, more than doubling the company's valuation of $2.35 billion announced in April 2020.
  • The Global 2000 relies on Collibra to create the critical alignment that accelerates workflows and delivers better results faster.
  • Sequoia Capital Global Equities (SCGE) is a public/private crossover fund, with investments spanning from late-stage private companies to public companies.